Pfizer raised its annual profit forecast due to cost cuts, better-than-expected sales of its COVID antiviral treatment, and high demand for its pneumonia vaccine. The company reported a first-quarter profit above Wall Street estimates.
Pfizer’s 44% Decline In Profits Still Tops Estimates—Stock Bounces From Decade Low https://t.co/zBr1vo9PFR
Pfizer lifted its annual earnings forecast and reported a first-quarter profit above Wall Street estimates, boosted by cost-cutting efforts and stronger-than-expected sales of its COVID antiviral treatment. Read more: https://t.co/L6d4AGnDVi https://t.co/e2dTTIDiyk
Pfizer lifted its annual profit forecast, banking on cost cuts, a smaller-than-feared drop in sales for its COVID antiviral treatment and strong demand for its pneumonia vaccine https://t.co/0gaocb2v5E https://t.co/Ng1aVBZxue
Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, boosted by cost cutting efforts and stronger-than-expected sales of its COVID antiviral treatment. https://t.co/CWMpw7DOhq https://t.co/CWMpw7DOhq
Pfizer lifts profit forecast as CEO sees reason for optimism in 2024 https://t.co/3hnzY7A7oy
📽️ WATCH - PFIZER LIFTS PROFIT VIEW ON COST CUTS, SMALLER DROP IN PAXLOVID Pfizer lifted its annual profit forecast, banking on cost cuts, a smaller-than-feared drop in sales for its COVID antiviral treatment and strong demand for its pneumonia vaccine, sending its shares up… https://t.co/FHETi51EM0
Pfizer lifted its annual profit forecast, banking on cost cuts, a smaller-than-feared drop in sales for its COVID antiviral treatment and strong demand for its pneumonia vaccine. More here: https://t.co/L6d4AGobKQ https://t.co/lGjsmZB4av